RFS by cytogenetic risk category and individual high-risk lesion. (A) RFS by cytogenetic risk category, defined as the time from onset of remission to relapse in the patients who achieved a complete response. Data were censored for allogeneic HSCT or other alternative therapy during remission (HSCT: n = 7 [high], 3 [intermediate], 4 [favorable], 9 [uninformative]; alternative therapy: n = 5 [high], 1 [intermediate], 7 [favorable], 9 [uninformative]). (B) RFS for KMT2A-rearrangment compared with all others (HSCT: n = 0 [KMT2A rearrangement], 22 [all others]; alternative therapy: n = 0 [KMT2A rearrangement], 23 [all others]). (C) RFS for Ph⁺ stratum compared with all others (HSCT: n = 0 [Ph+], 22 [all others]; alternative therapy: n = 4 [Ph+], 19 [all others]). (D) RFS for Ph-like stratum compared with all others (HSCT: n = 6 [Ph-like], 17 [all others]; alternative therapy: n = 1 [Ph-like], 21 [all others]). (E) RFS for infant leukemia with KMT2A rearrangement compared with all others (HSCT: n = 0 [KMT2A rearrangement], 22 [all others]; alternative therapy: n = 0 [KMT2A rearrangement], 23 [all others]). Tick marks indicate the time of censoring.